Climb Bio’s (CLYM) “Buy” Rating Reiterated at HC Wainwright

Climb Bio (NASDAQ:CLYM)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Wednesday, Marketbeat reports. They currently have a $20.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 62.60% from the company’s previous close.

A number of other brokerages have also recently commented on CLYM. Weiss Ratings reissued a “sell (d-)” rating on shares of Climb Bio in a research report on Monday, April 20th. Guggenheim started coverage on shares of Climb Bio in a report on Monday, June 8th. They set a “buy” rating and a $35.00 price target on the stock. Robert W. Baird set a $21.00 target price on Climb Bio in a research note on Wednesday, May 6th. Chardan Capital began coverage on Climb Bio in a research report on Tuesday, May 5th. They set a “buy” rating and a $22.00 price objective on the stock. Finally, Mizuho assumed coverage on shares of Climb Bio in a report on Wednesday, April 15th. They set an “outperform” rating and a $18.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $21.73.

Climb Bio Stock Up 1.0%

Shares of CLYM stock opened at $12.30 on Wednesday. The stock has a market cap of $704.30 million, a price-to-earnings ratio of -15.77 and a beta of 0.09. The business’s fifty day moving average is $10.57 and its 200 day moving average is $7.21. Climb Bio has a twelve month low of $1.18 and a twelve month high of $12.58.

Climb Bio (NASDAQ:CLYM) last announced its earnings results on Thursday, May 7th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.06. Equities research analysts expect that Climb Bio will post -0.87 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Climb Bio

A number of hedge funds have recently modified their holdings of CLYM. AQR Capital Management LLC purchased a new position in Climb Bio during the first quarter valued at $27,000. Qube Research & Technologies Ltd purchased a new stake in Climb Bio in the 2nd quarter worth approximately $43,000. Virtu Financial LLC purchased a new stake in Climb Bio in the 4th quarter worth approximately $43,000. Blair William & Co. IL bought a new stake in Climb Bio during the 4th quarter worth approximately $44,000. Finally, Marshall Wace LLP bought a new stake in Climb Bio during the 2nd quarter worth approximately $46,000. Institutional investors own 69.76% of the company’s stock.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.